

Richard Fedorak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5928115/publications.pdf>

Version: 2024-02-01

250
papers

28,348
citations

9428

76
h-index

6349

163
g-index

251
all docs

251
docs citations

251
times ranked

18737
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregnancy-Related Beliefs and Concerns of Inflammatory Bowel Disease Patients Modified After Accessing e-Health Portal. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 27-35.	0.1	7
2	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1909-1916.	0.9	34
3	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2354-2372.	1.1	23
4	The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. <i>PharmacoEconomics - Open</i> , 2019, 3, 591-597.	0.9	3
5	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	1.2	6
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
7	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1515-1524.e4.	2.4	14
8	A BACH2 Gene Variant Is Associated with Postoperative Recurrence of Crohn's Disease. <i>Journal of the American College of Surgeons</i> , 2018, 226, 902-908.	0.2	9
9	Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 101-110.	0.9	10
10	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	1.9	31
11	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	2.4	41
12	A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 861-870.	0.9	24
13	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	2.4	44
14	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn's Disease. <i>Nutrients</i> , 2018, 10, 1761.	1.7	61
15	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.1	34
16	Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease. <i>Scientific Reports</i> , 2018, 8, 9734.	1.6	10
17	Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2483-2493.	0.9	18
18	Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. <i>Gut</i> , 2017, 66, 863-871.	6.1	237

#	ARTICLE	IF	CITATIONS
19	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1232-1243.	1.9	141
20	Biosimilars in the Treatment of Inflammatory Bowel Disease. , 2017, , 471-479.		0
21	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	0.8	35
22	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 833-839.	0.9	94
23	Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. <i>International Journal of Colorectal Disease</i> , 2017, 32, 741-743.	1.0	19
24	The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. <i>EBioMedicine</i> , 2017, 21, 188-196.	2.7	20
25	Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2017, 7, 767-770.	0.4	17
26	Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. <i>Metabolites</i> , 2017, 7, 32.	1.3	30
27	Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis. <i>PLoS ONE</i> , 2017, 12, e0184660.	1.1	5
28	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , 2017, 23, 3890.	1.4	28
29	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-11.	0.8	6
30	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-9.	0.8	20
31	Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 92-99.	0.9	23
32	Ulcerative Colitis Patients With <i>Clostridium difficile</i> are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 691-704.	0.2	56
33	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1895-1902.	1.1	9
34	Urine-based metabolomic analysis of patients with <i>Clostridium difficile</i> infection: a pilot study. <i>Metabolomics</i> , 2016, 12, 1.	1.4	6
35	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 870-879.	0.9	63
36	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, e1-e2.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. <i>Digestive Diseases</i> , 2016, 34, 112-121.	0.8	7
38	A 29-year-old woman with Crohn disease considering pregnancy. <i>Cmaj</i> , 2016, 188, 131-132.	0.9	0
39	Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1817-1824.	0.9	3
40	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 675-682.	1.1	41
41	Metagenomic Analysis of Microbiome in Colon Tissue from Subjects with Inflammatory Bowel Diseases Reveals Interplay of Viruses and Bacteria. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	100
42	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1170-1181.	1.9	86
43	Fecal Microbial Transplant After Ileocolic Resection Reduces Ileitis but Restores Colitis in IL-10 ^{-/-} Mice. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1479-1490.	0.9	13
44	Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	16
45	Clinicians' Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 369-372.	0.8	58
46	Inflammatory Bowel Disease Patients Are Frequently Nonadherent to Scheduled Induction and Maintenance Infliximab Therapy: A Canadian Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 309-314.	0.8	12
47	Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 148, 1311-1319.e6.	0.6	204
48	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2015, 63, 320-328.	1.8	170
49	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	0.6	323
50	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	2.4	181
51	Don't Forget the Doctor: Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease. <i>JMIR MHealth and UHealth</i> , 2015, 3, e5.	1.8	14
52	TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. <i>World Journal of Gastroenterology</i> , 2015, 21, 10358.	1.4	15
53	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 181.	0.5	19
54	Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. <i>World Journal of Gastroenterology</i> , 2014, 20, 4934.	1.4	95

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps. <i>Clinical and Translational Gastroenterology</i> , 2014, 5, e54.	1.3	36
56	Disease manifestations of <i>Helicobacter pylori</i> infection in Arctic Canada: using epidemiology to address community concerns. <i>BMJ Open</i> , 2014, 4, e003689.	0.8	25
57	Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1044-1055.	1.9	40
58	The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 629-638.	1.9	88
59	Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2353-2363.	0.9	20
60	Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab. <i>Gastroenterology</i> , 2014, 146, S-457-S-458.	0.6	2
61	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 681-688.e1.	0.6	294
62	Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1871-1878.e8.	2.4	11
63	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1454-1463.	0.6	43
64	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
65	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 434-442.e1.	2.4	56
66	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 571-581.	0.6	66
67	Murine Ileocolic Bowel Resection with Primary Anastomosis. <i>Journal of Visualized Experiments</i> , 2014, , e52106.	0.2	3
68	Urine-based test for detection of colonic polyps: the coming of age. <i>Colorectal Cancer</i> , 2014, 3, 239-241.	0.8	0
69	Distance management of inflammatory bowel disease: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 829.	1.4	64
70	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e42-e48.	0.6	103
71	Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature. <i>BMC Gastroenterology</i> , 2013, 13, 59.	0.8	32
72	Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 711-721.	13.9	2,001

#	ARTICLE	IF	CITATIONS
73	Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 252-262.	1.9	167
74	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013, 77, 624-630.	0.5	49
75	Commentary: larazotide acetate – an exciting new development for coeliac patients? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 496-497.	1.9	1
76	Celiac Disease in Children With Inflammatory Bowel Disease: a Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2013, 108, 455-456.	0.2	6
77	A Machine-Learned Predictor of Colonic Polyps Based on Urinary Metabolomics. <i>BioMed Research International</i> , 2013, 2013, 1-11.	0.9	33
78	A randomised phase I study of etrolizumab (rhuMAB \hat{I}^{27}) in moderate to severe ulcerative colitis. <i>Gut</i> , 2013, 62, 1122-1130.	6.1	134
79	Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1248-1254.	1.9	40
80	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 447-459.	1.9	96
81	Epithelial Cell Extrusion Leads to Breaches in the Intestinal Epithelium. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 912-921.	0.9	23
82	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2013, 19, 3347.	1.4	28
83	Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. <i>PLoS ONE</i> , 2013, 8, e67017.	1.1	12
84	Metabolomic Profiles Are Gender, Disease and Time Specific in the Interleukin-10 Gene-Deficient Mouse Model of Inflammatory Bowel Disease. <i>PLoS ONE</i> , 2013, 8, e67654.	1.1	17
85	Environment and the Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, e18-e24.	1.8	121
86	Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e19.	1.3	40
87	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 468-481.	1.1	321
88	Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. <i>World Journal of Gastroenterology</i> , 2012, 18, 5058.	1.4	22
89	Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. <i>Journal of Surgical Research</i> , 2012, 178, 147-154.	0.8	7
90	Probiotic Bacteria in the Prevention and the Treatment of Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 821-842.	1.0	21

#	ARTICLE	IF	CITATIONS
91	Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2012, 143, 1461-1469.	0.6	49
92	Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 207-214.	0.6	57
93	Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: A systematic review and meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 267-275.	0.6	123
94	Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 777-786.	0.6	14
95	The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 1657-1664.	1.0	53
96	Patients with Inflammatory Bowel Disease Exhibit Dysregulated Responses to Microbial DNA. <i>PLoS ONE</i> , 2012, 7, e37932.	1.1	34
97	Development and Validation of an Administrative Case Definition for Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 711-717.	1.8	82
98	Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 34-40.	0.9	86
99	Intravenous Injection of Endogenous Microbial Components Abrogates DSS-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 345-354.	1.1	8
100	Epithelial Gaps in a Rodent Model of Inflammatory Bowel Disease: A Quantitative Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2011, 2, e3.	1.3	6
101	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 1174-1180.	0.5	70
102	A Novel Highly Sensitive Test for Detecting Colon Cancer Using Spot Urine Metabolomics. <i>Gastroenterology</i> , 2011, 140, S-40.	0.6	2
103	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	6.1	750
104	Predicting, Treating and Preventing Postoperative Recurrence of Crohn's Disease: The State of the Field. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 140-146.	1.8	13
105	Health Care Resource Use and Costs for Crohn's Disease before and after Infliximab Therapy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 497-502.	1.8	25
106	Patients With IBD are Exposed to High Levels of Ionizing Radiation Through CT Scan Diagnostic Imaging. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 34-39.	1.1	117
107	Mind The Gaps. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 240-245.	1.1	64
108	Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 787-797.	1.1	28

#	ARTICLE	IF	CITATIONS
109	A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 181-187.	1.9	35
110	Neonatal exposure to fecal antigens reduces intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 899-906.	0.9	5
111	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. , 2011, , 123-150.		2
112	Oral Administration of Curcumin Emulsified in Carboxymethyl Cellulose Has a Potent Anti-inflammatory Effect in the IL-10 Gene-Deficient Mouse Model of IBD. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1272-1277.	1.1	55
113	Naturally Occurring Glycoalkaloids in Potatoes Aggravate Intestinal Inflammation in Two Mouse Models of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3078-3085.	1.1	28
114	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1209-1218.	0.9	82
115	Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 522-528.	1.9	95
116	Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1129-1134.	1.9	81
117	An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens. <i>Clinical and Experimental Immunology</i> , 2010, 161, 187-196.	1.1	17
118	A Randomized Trial of Topical Anesthesia Comparing Lidocaine Versus Lidocaine Plus Xylometazoline for Unsedated Transnasal Upper Gastrointestinal Endoscopy. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 317-321.	1.8	16
119	Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2010, 24, 651-655.	1.8	21
120	Tumor Necrosis Factor- α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology. <i>Gastroenterology Clinics of North America</i> , 2010, 39, 543-557.	1.0	39
121	Metabolomics and detection of colorectal cancer in humans: a systematic review. <i>Future Oncology</i> , 2010, 6, 1395-1406.	1.1	90
122	Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 44-49.	0.5	81
123	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2010, 138, S-167-S-168.	0.6	15
124	Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 688-695.e2.	2.4	142
125	Probiotics in the management of ulcerative colitis. <i>Gastroenterology and Hepatology</i> , 2010, 6, 688-90.	0.2	10
126	Long-Term Response Rates to Infliximab Therapy for Crohn's Disease in an Outpatient Cohort. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 348-352.	1.8	36

#	ARTICLE	IF	CITATIONS
127	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 185-202.	1.8	37
128	Does Smoking Reduce Infliximab's Effectiveness against Crohn's Disease?. Canadian Journal of Gastroenterology & Hepatology, 2009, 23, 121-125.	1.8	18
129	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Gut, 2009, 58, 1354-1362.	6.1	49
130	Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. Microbial Ecology in Health and Disease, 2009, 21, 33-37.	3.8	6
131	Bacterial Overgrowth and Inflammation of Small Intestine After Carboxymethylcellulose Ingestion in Genetically Susceptible Mice. Inflammatory Bowel Diseases, 2009, 15, 359-364.	0.9	141
132	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflammatory Bowel Diseases, 2009, 15, 760-768.	0.9	119
133	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1599-1604.	0.9	93
134	Pneumococcal Pneumonia: Potential for Diagnosis through a Urinary Metabolic Profile. Journal of Proteome Research, 2009, 8, 5550-5558.	1.8	93
135	Probiotics in Ulcerative Colitis. , 2009, , 181-194.		0
136	CD4+CD25+ Regulatory T Cells Have Divergent Effects on Intestinal Inflammation in IL-10 Gene-Deficient Mice. Digestive Diseases and Sciences, 2008, 53, 1544-1552.	1.1	0
137	Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF α , improves health-related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease, 2008, 23, 289-296.	1.0	51
138	A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease. Gastroenterology, 2008, 135, 1130-1141.	0.6	709
139	Allopurinol to Prevent Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2008, 6, 465-471.	2.4	29
140	Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the $\alpha 4\beta 7$ Integrin. Clinical Gastroenterology and Hepatology, 2008, 6, 1370-1377.	2.4	283
141	Urinary Metabolic Profiles of Inflammatory Bowel Disease in Interleukin-10 Gene-Deficient Mice. Analytical Chemistry, 2008, 80, 5524-5531.	3.2	70
142	Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent?. Journal of Medical Microbiology, 2008, 57, 111-117.	0.7	24
143	Understanding Why Probiotic Therapies Can be Effective in Treating IBD. Journal of Clinical Gastroenterology, 2008, 42, S111-S115.	1.1	40
144	Recommendations for Probiotic Use [©] 2008. Journal of Clinical Gastroenterology, 2008, 42, S104-S108.	1.1	120

#	ARTICLE	IF	CITATIONS
145	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 261-272.	1.8	10
146	<i>Helicobacter Pylori</i> Infection in Canada's Arctic: Searching for the Solutions. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 912-916.	1.8	19
147	VSL#3 Probiotic Upregulates Intestinal Mucosal Alkaline Sphingomyelinase and Reduces Inflammation. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 237-242.	1.8	69
148	Exercise and Inflammatory Bowel Disease. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 497-504.	1.8	65
149	Early Experience with Unsedated Ultrathin 4.9 mm Transnasal Gastroscopy: A Pilot Study. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 917-922.	1.8	9
150	Canadian Digestive Health Foundation: Interview with the New President, Dr Richard Fedorak. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 345-346.	1.8	1
151	Oropharyngeal Crohn's disease. Clinical and Experimental Gastroenterology, 2008, 1, 15.	1.0	9
152	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut, 2007, 56, 1232-1239.	6.1	866
153	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, S22-S28.	0.2	4
154	Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. American Journal of Clinical Nutrition, 2007, 85, 816-823.	2.2	153
155	Vertebral Fractures and Role of Low Bone Mineral Density in Crohn's Disease. Clinical Gastroenterology and Hepatology, 2007, 5, 721-728.	2.4	46
156	Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. Gastroenterology, 2007, 132, 1672-1683.	0.6	586
157	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21-23, 2006. Gastroenterology, 2007, 133, 312-339.	0.6	197
158	Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. Inflammatory Bowel Diseases, 2007, 13, 947-954.	0.9	35
159	The role of probiotics in management of irritable bowel syndrome. Current Gastroenterology Reports, 2007, 9, 393-400.	1.1	15
160	Probiotics in the Management of Inflammatory Bowel Diseases?. American Journal of Gastroenterology, 2007, 102, 22-28.	0.2	0
161	Probiotic Therapies for IBD. Gastroenterology and Hepatology, 2007, 3, 180-1.	0.2	0
162	Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial. Gastroenterology, 2006, 130, 323-333.	0.6	1,523

#	ARTICLE	IF	CITATIONS
163	Onercept for Moderate-to-Severe Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 888-893.	2.4	65
164	Probiotics in the Treatment of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 260-263.	1.1	78
165	Recommendations for Probiotic Use. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 275-278.	1.1	56
166	Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 429-436.	0.9	15
167	A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor- α gene-deficient mice. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 750-757.	0.9	9
168	The role of antibiotic and probiotic therapies in current and future management of inflammatory Bowel disease. <i>Current Gastroenterology Reports</i> , 2006, 8, 486-498.	1.1	37
169	The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study. <i>American Journal of Gastroenterology</i> , 2006, 101, 1559-1568.	0.2	522
170	The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. <i>Journal of Medical Microbiology</i> , 2006, 55, 1141-1149.	0.7	211
171	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. <i>Advanced Drug Delivery Reviews</i> , 2005, 57, 303-316.	6.6	82
172	Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 765-777.	0.9	48
173	Association with Selected Bacteria Does Not Cause Enterocolitis in IL-10 Gene-Deficient Mice Despite a Systemic Immune Response. <i>Digestive Diseases and Sciences</i> , 2005, 50, 905-913.	1.1	29
174	Effects of Formal Education for Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 235-244.	1.8	121
175	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1539-1546.	0.2	659
176	Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 122-132.	2.4	78
177	Treatment of Ulcerative Colitis with a Humanized Antibody to the $\alpha 4\beta 7$ Integrin. <i>New England Journal of Medicine</i> , 2005, 352, 2499-2507.	13.9	736
178	The Role of Enteric Microflora in Inflammatory Bowel Disease: Human and Animal Studies with Probiotics and Prebiotics. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 465-482.	1.0	51
179	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <i>Current Opinion in Pharmacology</i> , 2005, 5, 596-603.	1.7	112
180	A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2005, 129, 807-818.	0.6	571

#	ARTICLE	IF	CITATIONS
181	Probiotics in the management of inflammatory bowel disease. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 19.	0.2	2
182	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004, 18, 503-508.	1.8	25
183	Endoscopic Perforation Rates at a Canadian University Teaching Hospital. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2004, 18, 221-226.	1.8	56
184	Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. <i>New England Journal of Medicine</i> , 2004, 350, 876-885.	13.9	2,026
185	Bones and Crohn's. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 220-228.	0.9	71
186	Probiotics and the Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 286-299.	0.9	155
187	Is it time to re-classify Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 99-106.	1.0	11
188	Conservative approach to severe ulcerative colitis. <i>Digestive and Liver Disease</i> , 2004, 36, 4-6.	0.4	1
189	Probiotics and prebiotics in gastrointestinal disorders. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 146-155.	1.0	108
190	Lack of Interleukin-10 Leads to Intestinal Inflammation, Independent of the Time at Which Luminal Microbial Colonization Occurs. <i>Inflammatory Bowel Diseases</i> , 2003, 9, 87-97.	0.9	57
191	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , 2003, 124, A377.	0.6	28
192	The Frequency of Vitamin D Deficiency in Adults with Crohn's Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 473-478.	1.8	91
193	Potato Glycoalkaloids Adversely Affect Intestinal Permeability and Aggravate Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 340-346.	0.9	84
194	Normal Breast Milk Limits the Development of Colitis in IL-10 Deficient Mice. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 390-398.	0.9	31
195	A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1627-1632.	13.9	704
196	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , 2000, 118, A874.	0.6	81
197	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1461-1472.	0.6	442
198	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 1473-1482.	0.6	490

#	ARTICLE	IF	CITATIONS
199	Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , 2000, 118, 1094-1105.	0.6	215
200	Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1565-1584.	1.9	86
201	Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , 1999, 116, 1107-1114.	0.6	710
202	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. <i>Gastroenterology</i> , 1999, 117, 527-535.	0.6	236
203	Interleukin-10 Gene-Deficient Mice Develop a Primary Intestinal Permeability Defect in Response to Enteric Microflora. <i>Inflammatory Bowel Diseases</i> , 1999, 5, 262-270.	0.9	259
204	Endogenous Interleukin-10 Regulates Hemodynamic Parameters, Leukocyte-Endothelial Cell Interactions, and Microvascular Permeability During Endotoxemia. <i>Circulation Research</i> , 1998, 83, 1124-1131.	2.0	73
205	Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. <i>Gastroenterology</i> , 1997, 113, 383-389.	0.6	484
206	Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. <i>Gastroenterology</i> , 1997, 113, 151-159.	0.6	161
207	A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. <i>Gastroenterology</i> , 1997, 112, 1069-1077.	0.6	170
208	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. , 1997, 18, 681-695.		8
209	Small Intestinal Function Following Syngeneic Transplantation in the Rat. <i>Journal of Surgical Research</i> , 1996, 61, 379-384.	0.8	28
210	Increased permeability occurs in rat ileum following induction of pancolitis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 405-411.	1.1	13
211	Nutritional and intestinal effects of the novel immunosuppressive agents: Deoxyspergualin, rapamycin, and mycophenolate mofetil. <i>Clinical Biochemistry</i> , 1996, 29, 363-369.	0.8	15
212	TACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1. <i>Transplantation</i> , 1996, 61, 630-634.	0.5	24
213	Insulin downregulates diabetic-enhanced intestinal glucose transport rapidly in ileum and slowly in jejunum. <i>Canadian Journal of Physiology and Pharmacology</i> , 1996, 74, 1294-301.	0.7	5
214	Budesonide-glucuronide: A Potential Prodrug for Treatment of Ulcerative Colitis. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 677-681.	1.6	23
215	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , 1995, 38, 403-412.	2.9	23
216	A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. <i>American Journal of Physiology - Renal Physiology</i> , 1995, 269, G210-G218.	1.6	1

#	ARTICLE	IF	CITATIONS
217	Methotrexate for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1995, 332, 292-297.	13.9	920
218	Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. <i>Gastroenterology</i> , 1995, 108, 1688-1699.	0.6	38
219	FK506 increases permeability in rat intestine by inhibiting mitochondrial function. <i>Gastroenterology</i> , 1995, 109, 107-114.	0.6	75
220	The buried gastrostomy bumper syndrome: prevention and endoscopic approaches to removal. <i>Gastrointestinal Endoscopy</i> , 1995, 41, 505-508.	0.5	89
221	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , 1995, 38, 403-412.	2.9	0
222	A budesonide prodrug accelerates treatment of colitis in rats.. <i>Gut</i> , 1994, 35, 1439-1446.	6.1	48
223	Low-Dose Cyclosporine for the Treatment of Crohn's Disease. <i>New England Journal of Medicine</i> , 1994, 330, 1846-1851.	13.9	256
224	Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. <i>Gastroenterology</i> , 1994, 106, 287-296.	0.6	688
225	A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. <i>Gastroenterology</i> , 1994, 106, 405-413.	0.6	40
226	Acetic acid-induced colitis results in bystander ileal injury. <i>Agents and Actions</i> , 1993, 38, 76-84.	0.7	10
227	Jejunum is preferable for construction of a bianchi bowel-lengthening procedure in swine short bowel. <i>Journal of Pediatric Surgery</i> , 1993, 28, 102-109.	0.8	12
228	Oral Vanadate Reduces Na ⁺ -Dependent Glucose Transport in Rat Small Intestine. <i>Diabetes</i> , 1993, 42, 1126-1132.	0.3	20
229	INTESTINAL FUNCTION FOLLOWING ALLOGENEIC SMALL INTESTINAL TRANSPLANTATION IN THE RAT. <i>Transplantation</i> , 1992, 53, 264-271.	0.5	38
230	Food consistency effects of quarg in lactose malabsorption. <i>International Dairy Journal</i> , 1992, 2, 257-269.	1.5	20
231	Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1992, 45, 275-281.	1.0	11
232	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. <i>Digestive Diseases and Sciences</i> , 1992, 37, 205-214.	1.1	79
233	Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. <i>Gastroenterology</i> , 1992, 102, 1229-35.	0.6	7
234	Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991, 69, 480-487.	0.7	52

#	ARTICLE	IF	CITATIONS
235	Adaptation of intestinal glucose transport in rats with diabetes mellitus occurs independent of hyperphagia. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991, 69, 1143-1148.	0.7	16
236	Diabetes Mellitus and Glucagon Alter Ouabain-Sensitive Na ⁺ -K ⁺ -ATPase in Rat Small Intestine. <i>Diabetes</i> , 1991, 40, 1603-1610.	0.3	14
237	Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats. <i>American Journal of Physiology - Renal Physiology</i> , 1991, 261, G585-G591.	1.6	42
238	Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. <i>Gastroenterology</i> , 1990, 98, 615-625.	0.6	141
239	The physiology of adaptation to small bowel resection in the pig: An integrated study of morphological and functional changes. <i>Journal of Pediatric Surgery</i> , 1990, 25, 650-657.	0.8	53
240	Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. <i>Digestive Diseases and Sciences</i> , 1989, 34, 567-572.	1.1	13
241	Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 1989, 38, 43-48.	1.0	19
242	Inhibition of Cholera-Toxin-Stimulated Intestinal Secretion by CGS 9343B in Rats. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1989, 8, 252-258.	0.9	4
243	In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. <i>Gastroenterology</i> , 1988, 94, 1343-1350.	0.6	26
244	Antidiarrheal therapy. <i>Digestive Diseases and Sciences</i> , 1987, 32, 195-205.	1.1	24
245	Intestinal adaptation to diabetes. Altered Na-dependent nutrient absorption in streptozocin-treated chronically diabetic rats. <i>Journal of Clinical Investigation</i> , 1987, 79, 1571-1578.	3.9	60
246	Experimental diabetic diarrhea in rats. <i>Gastroenterology</i> , 1986, 91, 564-569.	0.6	62
247	Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. <i>Gastroenterology</i> , 1986, 91, 564-9.	0.6	19
248	Treatment of Diabetic Diarrhea with Clonidine. <i>Annals of Internal Medicine</i> , 1985, 102, 197.	2.0	170
249	Short Bowel Syndrome. , 0, , 1295-1321.		0
250	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. <i>Inflammatory Bowel Diseases</i> , 0, 5, 262-270.	0.9	30